1. Stem Cells and Regenerative Medicine
  2. Genetics and Genomics

Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6

  1. Rasmus O Bak
  2. Daniel P Dever
  3. Andreas Reinisch
  4. David Cruz Hernandez
  5. Ravindra Majeti  Is a corresponding author
  6. Matthew H Porteus  Is a corresponding author
  1. Stanford University, United States
https://doi.org/10.7554/eLife.27873
Share this article
Cite this article
  1. Rasmus O Bak
  2. Daniel P Dever
  3. Andreas Reinisch
  4. David Cruz Hernandez
  5. Ravindra Majeti
  6. Matthew H Porteus
(2017)
Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6
eLife 6:e27873.
https://doi.org/10.7554/eLife.27873
  2. Download BibTeX
  3. Download .RIS

Abstract

Precise and efficient manipulation of genes is crucial for understanding the molecular mechanisms that govern human hematopoiesis and for developing novel therapies for diseases of the blood and immune system. Current methods do not enable precise engineering of complex genotypes that can be easily tracked in a mixed population of cells. We describe a method to multiplex homologous recombination (HR) in human hematopoietic stem and progenitor cells and primary human T cells by combining rAAV6 donor delivery and the CRISPR/Cas9 system delivered as ribonucleoproteins (RNPs). In addition, the use of reporter genes allows FACS-purification and tracking of cells that have had multiple alleles or loci modified by HR. We believe this method will enable broad applications not only to the study of human hematopoietic gene function and networks, but also to perform sophisticated synthetic biology to develop innovative engineered stem cell-based therapeutics.

Article and author information

Author details

  1. Rasmus O Bak

    Department of Pediatrics, Stanford University, Stanford, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7383-0297

  2. Daniel P Dever

    Department of Pediatrics, Stanford University, Stanford, United States
    Competing interests
    No competing interests declared.

  3. Andreas Reinisch

    Department of Medicine, Division of Hematology, Stanford University, Stanford, United States
    Competing interests
    No competing interests declared.

  4. David Cruz Hernandez

    Department of Medicine, Division of Hematology, Stanford University, Stanford, United States
    Competing interests
    No competing interests declared.

  5. Ravindra Majeti

    Department of Medicine, Division of Hematology, Stanford University, Stanford, United States
    For correspondence
    rmajeti@stanford.edu
    Competing interests
    Ravindra Majeti, has equity and consults for Forty Seven Inc..

  6. Matthew H Porteus

    Department of Pediatrics, Stanford University, Stanford, United States
    For correspondence
    mporteus@stanford.edu
    Competing interests
    Matthew H Porteus, has equity and consults for CRISPR Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3850-4648

Funding

Danish Council for Independent Research (DFF-1333-00106B)

  • Rasmus O Bak

Danish Council for Independent Research (DFF-1331-00735B)

  • Rasmus O Bak

National Institutes of Health (R01- AI097320)

  • Matthew H Porteus

National Institutes of Health (R01-AI120766)

  • Matthew H Porteus

Stanford Child Health Research Institute (Postdoctoral Award)

  • Daniel P Dever

Austrian Research Council (Erwin Schroedinger Postdoctoral Fellowship)

  • Andreas Reinisch

Amon G. Carter Foundation

  • Matthew H Porteus

Laurie Kraus Lacob Faculty Scholar Award in Pediatric Translational Research (Scholar Award)

  • Matthew H Porteus

National Institutes of Health (PN2EY018244)

  • Matthew H Porteus

Stanford Ludwig Center for Cancer Stem Cell Research

  • Ravindra Majeti

National Institutes of Health (R01-CA188055)

  • Ravindra Majeti

New York Stem Cell Foundation (Robertson Investigator)

  • Ravindra Majeti

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animal experiments were performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The experimental protocol was approved by Stanford University's Administrative Panel on Lab Animal Care (IACUC 25065).

Copyright

© 2017, Bak et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 8,516
    views
  • 1,743
    downloads
  • 93
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Rasmus O Bak
  2. Daniel P Dever
  3. Andreas Reinisch
  4. David Cruz Hernandez
  5. Ravindra Majeti
  6. Matthew H Porteus
(2017)
Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6
eLife 6:e27873.
https://doi.org/10.7554/eLife.27873

Share this article

https://doi.org/10.7554/eLife.27873

Categories and tags

Research organisms

Further reading

    1. Developmental Biology
    2. Stem Cells and Regenerative Medicine

    SMARCAD1 and TOPBP1 contribute to heterochromatin maintenance at the transition from the 2C-like to the pluripotent state

    Ruben Sebastian-Perez, Shoma Nakagawa ... Maria Pia Cosma
    Research Article

    Chromocenters are established after the 2-cell (2C) stage during mouse embryonic development, but the factors that mediate chromocenter formation remain largely unknown. To identify regulators of 2C heterochromatin establishment in mice, we generated an inducible system to convert embryonic stem cells (ESCs) to 2C-like cells. This conversion is marked by a global reorganization and dispersion of H3K9me3-heterochromatin foci, which are then reversibly formed upon re-entry into pluripotency. By profiling the chromatin-bound proteome (chromatome) through genome capture of ESCs transitioning to 2C-like cells, we uncover chromatin regulators involved in de novo heterochromatin formation. We identified TOPBP1 and investigated its binding partner SMARCAD1. SMARCAD1 and TOPBP1 associate with H3K9me3-heterochromatin in ESCs. Interestingly, the nuclear localization of SMARCAD1 is lost in 2C-like cells. SMARCAD1 or TOPBP1 depletion in mouse embryos leads to developmental arrest, reduction of H3K9me3, and remodeling of heterochromatin foci. Collectively, our findings contribute to comprehending the maintenance of chromocenters during early development.

    1. Stem Cells and Regenerative Medicine

    Il-6 signaling exacerbates hallmarks of chronic tendon disease by stimulating reparative fibroblasts

    Tino Stauber, Greta Moschini ... Jess G Snedeker
    Research Article

    Tendinopathies are debilitating diseases currently increasing in prevalence and associated costs. There is a need to deepen our understanding of the underlying cell signaling pathways to unlock effective treatments. In this work, we screen cell signaling pathways in human tendinopathies and find positively enriched IL-6/JAK/STAT signaling alongside signatures of cell populations typically activated by IL-6 in other tissues. In human tendinopathic tendons, we also confirm the strong presence and co-localization of IL-6, IL-6R, and CD90, an established marker of reparative fibroblasts. To dissect the underlying causalities, we combine IL-6 knock-out mice with an explant-based assembloid model of tendon damage to successfully connect IL-6 signaling to reparative fibroblast activation and recruitment. Vice versa, we show that these reparative fibroblasts promote the development of tendinopathy hallmarks in the damaged explant upon IL-6 activation. We conclude that IL-6 activates tendon fibroblast populations which then initiate and deteriorate tendinopathy hallmarks.